The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Pathophysiology of Diabetes Mellitus in Cushing’s Syndrome
Abstract
Cushing’s syndrome is commonly complicated with an impairment of glucose metabolism, which is often clinically manifested as diabetes mellitus. The development of diabetes mellitus in Cushing’s syndrome is both a direct and indirect consequence of glucocorticoid excess. Indeed, glucocorticoid excess induces a stimulation of gluconeogenesis in the liver as well as an inhibition of insulin sensitivity both in the liver and in the skeletal muscles, which represent the most important sites responsible for glucose metabolism. In particular, glucocorticoid excess stimulates the expression of several key enzymes involved in the process of gluconeogenesis, with a consequent increase of glucose production, and induces an impairment of insulin sensitivity either directly by interfering with the insulin receptor signaling pathway or indirectly, through the stimulation of lipolysis and proteolysis and the consequent increase of fatty acids and amino acids, which contribute to the development of insulin resistance. Moreover, the peculiar distribution of adipose tissue throughout the body, with the predominance of visceral adipose tissue, significantly contributes to the worsening of insulin resistance and the development of a metabolic syndrome, which participates in the occurrence and maintenance of the impairment of glucose tolerance. Finally, glucocorticoid excess is able to impair insulin secretion as well as act at the level of the pancreatic beta cells, where it inhibits different steps of the insulin secretion process. This phenomenon is probably responsible for the passage from an impairment of glucose tolerance to an overt diabetes mellitus in susceptible patients with Cushing’s syndrome.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This is the case in both endogenous and medication-induced hypercortisolism (Cushing's syndrome), with up to 70% of patients developing impaired glycaemic control ( 4 ).”
From Dynamic modulation of glucose utilisation by glucocorticoid rhythms in health and disease (2020) · cites this paper as [4]
In the citing paper
“with chronic CORT excess (hypercortisolism) commonly associated with the impairment of glucose metabolism and the development of secondary type 2 diabetes ( 3, 4 ).”
From Dynamic modulation of glucose utilisation by glucocorticoid rhythms in health and disease (2020) · cites this paper as [4]
In the citing paper
“and by stimulating liver gluconeogenesis and glycogenolysis ( 4, 15 ).”
From Dynamic modulation of glucose utilisation by glucocorticoid rhythms in health and disease (2020) · cites this paper as [4]
Citations
Cites
Adipose Tissue as an Endocrine Organ
Kershaw, E. E., & Flier, J. S. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0395 · Cited by 5,522
Kahn, S. E. (2003) · Diabetologia · doi:10.1007/s00125-002-1009-0 · Cited by 2,166
Glucocorticoids and insulin resistance: old hormones, new targets
ANDREWS, R. C., & WALKER, B. R. (1999) · Clinical Science · doi:10.1042/cs0960513 · Cited by 731
RIZZA, R. A., MANDARINO, L. J., & GERICH, J. E. (1982) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-54-1-131 · Cited by 696 · cited 1×
“This action mainly reflects on a decrease of glycogen synthesis and glucose uptake. The direct interference of GCs with the insulin receptor signaling pathway has been demonstrated mostly in animal by in vitro and in vivo studies, which confirmed that GCs do not influence insulin receptor expression but mainly induce…”
BackgroundGlucocorticoids, metabolism and metabolic diseases
Vegiopoulos, A., & Herzig, S. (2007) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2007.05.015 · Cited by 535
Van Raalte, D. H., Ouwens, D. M., & Diamant, M. (2009) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2008.02067.x · Cited by 439
Effects of glucocorticoids on carbohydrate metabolism
Mcmahon, M., Gerich, J., & Rizza, R. (1988) · Diabetes/Metabolism Reviews · doi:10.1002/dmr.5610040105 · Cited by 390
Saad, M. J., Folli, F., Kahn, J. A., & Kahn, C. R. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116803 · Cited by 349
Hormonal regulation of hepatic gluconeogenesis.
Kraus-Friedmann, N. (1984) · Physiological Reviews · doi:10.1152/physrev.1984.64.1.170 · Cited by 276
Ruzzin, J., Wagman, A. S., & Jensen, J. (2005) · Diabetologia · doi:10.1007/s00125-005-1886-0 · Cited by 243
Glucocorticoids and 11beta-Hydroxysteroid Dehydrogenase in Adipose Tissue
Seckl, J. R. (2004) · Recent Progress in Hormone Research · doi:10.1210/rp.59.1.359 · Cited by 239 · cited 1×
“2 Fig. 2. Effects of GCs on the insulin receptor signaling pathways. GC indicates the processes inhibited by GC excess. IRS-1 = Insulin receptor substrate-1; PI3K = phosphatidylinositol-3-kinase; PKB = protein kinase B; GSK-3 = glycogen synthase kinase-3. F02 Effects of GC Excess in Adipose Tissue GCs plays a pivotal…”
BackgroundHowlett, T. A., REES, L. H., & BESSER, G. M. (1985) · Clinics in Endocrinology and Metabolism · doi:10.1016/s0300-595x(85)80083-9 · Cited by 238
Pivonello, R., De Martino, M. C., De Leo, M., Lombardi, G., & Colao, A. (2008) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2007.10.010 · Cited by 195
Self-citationWeinstein, S. P., Wilson, C. M., Pritsker, A., & Cushman, S. W. (1998) · Metabolism · doi:10.1016/s0026-0495(98)90184-6 · Cited by 175
Ullrich, S., Berchtold, S., Ranta, F., Seebohm, G., Henke, G., Lupescu, A., Mack, A. F., Chao, C., Su, J., Nitschke, R., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.4.1090 · Cited by 175
Acute and 2-week exposure to prednisolone impair different aspects of β-cell function in healthy men
van Raalte, D. H., Nofrate, V., Bunck, M. C., van Iersel, T., Elassaiss Schaap, J., Nässander, U. K., Heine, R. J., Mari, A., Dokter, W. H. A., & Diamant, M. (2010) · European Journal of Endocrinology · doi:10.1530/eje-09-1034 · Cited by 170
Gremlich, S., Roduit, R., & Thorens, B. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.6.3216 · Cited by 155
Kooi, B. T. V., Onuma, H., Oeser, J. K., Svitek, C. A., Allen, S. R., Kooi, C. W. V., Chazin, W., & O’Brien, R. M. (2005) · Molecular Endocrinology · doi:10.1210/me.2004-0497 · Cited by 151
Resmini, E., Minuto, F., Colao, A., & Ferone, D. (2009) · Acta Diabetologica · doi:10.1007/s00592-009-0112-9 · Cited by 147
Self-citationMatsumoto, K., Yamasaki, H., Akazawa, S., Sakamaki, H., Ishibashi, M., Abiru, N., Uotani, S., Matsuo, H., Yamaguchi, Y., Tokuyama, K., et al. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.7.8675587 · Cited by 91
The effect of cortisol on glucose/glucose-6-phosphate cycle activity and insulin action.
Rooney, D. P., Neely, R. D., Cullen, C., Ennis, C. N., Sheridan, B., Atkinson, A. B., Trimble, E. R., & Bell, P. M. (1993) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.77.5.8077310 · Cited by 76
Effects of glucocorticoids on hepatic sensitivity to insulin and glucagon in man
Dirlewanger, M., Schneiter, P., Paquot, N., Jéquier, E., Rey, V., & Tappy, L. (2000) · Clinical Nutrition · doi:10.1054/clnu.1999.0064 · Cited by 52
Findling, J. W., & Raff, H. (2005) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2005.01.015 · Cited by 43
Borboni, P., Porzio, O., Magnaterra, R., Fusco, A., Sesti, G., Lauro, R. D., & Marlier, L. N. J. L. (1996) · Molecular and Cellular Endocrinology · doi:10.1016/0303-7207(95)03745-4 · Cited by 21
Flagged first, then by citations
Research works printed but not linked: 5
- 10.1042%2FCS19980388 · DOI
- 10.1210%2Fjc.77.5.1180 · DOI · Paper page
- 10.1007%2Fs00125-003-1190-9 · DOI · Paper page
- 10.1074%2Fjbc.272.48.30261 · DOI
- 10.1210%2Fjc.81.7.2621 · DOI
Cited by
Sorted by citations
Regulation of glucose homeostasis by glucocorticoids
Kuo, T., McQueen, A., Chen, T.-C., & Wang, J.-C. (2015) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4939-2895-8_5 · Cited by 723
Complications of Cushing's syndrome: state of the art
Pivonello, R., Isidori, A. M., Martino, M. C. D., Newell-Price, J. D. C., Biller, B. M. K., & Colao, A. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00086-3 · Cited by 694
Self-citationThe Treatment of Cushing's Disease
Pivonello, R., Leo, M. D., Cozzolino, A., & Colao, A. A. L. (2015) · Endocrine Reviews · doi:10.1210/er.2013-1048 · Cited by 478
Self-citationHyperglycemia Associated With Pasireotide: Results From a Mechanistic Study in Healthy Volunteers
Henry, R. R., Ciaraldi, T. P., Armstrong, D. A., Burke, P., Ligueros‐Saylan, M., & Mudaliar, S. R. D. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1771 · Cited by 256
Metabolic functions of glucocorticoid receptor in skeletal muscle
Kuo, T., Harris, C. A., & Wang, J.-C. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.03.003 · Cited by 254
Metadata
- Authors
- Pivonello, R., De Leo, M., Vitale, P., Cozzolino, A., Simeoli, C., De Martino, M. C., Lombardi, G., & Colao, A.
- Affiliations
- Federico II University Hospital (IT)
- Venue
- Neuroendocrinology
- Publisher
- S. Karger AG
- Published
- 2010
- Volume
- 92
- Issue
- Suppl. 1
- Pages
- 77-81
- ISSN
- 0028-3835 (ISSN-L)
- 1423-0194
- OpenAlex
- W2100232797
- Cited by
- 190
- References
- 24
- Citations by year
- 2026: 6 · 2025: 10 · 2024: 14 · 2023: 13 · 2022: 8 · 2021: 15 · 2020: 14 · 2019: 13 · 2018: 13 · 2017: 11 · 2016: 10 · 2015: 17 · 2014: 13 · 2013: 16 · 2012: 14
- FWCI
- 7.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neuroendocrinology (publishedVersion)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- Cushing's syndrome, diabetes mellitus, glucocorticoid excess, insulin resistance, insulin secretion, gluconeogenesis, glucose tolerance, visceral adipose tissue, metabolic syndrome, pancreatic beta cells, lipolysis
- MeSH terms
- Insulin Secretion, Cushing Syndrome, Diabetes Mellitus, Glucose, Humans, Insulin, Insulin Resistance, Insulin-Secreting Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
